Efficacy of omalizumab in moderate chronic rhinosinusitis with nasal polyps and IgE-mediated asthma

Area of Science:

• Otolaryngology
• Allergy and Immunology
• Pulmonology

Background:

• Limited evidence exists for biologic therapies in moderate chronic rhinosinusitis with nasal polyps (CRSwNP).
• Biologics are typically recommended for severe, uncontrolled CRSwNP.
• Investigating omalizumab's efficacy in moderate CRSwNP is crucial.

Purpose of the Study:

• To evaluate the effectiveness of omalizumab in patients with moderate CRSwNP and mild-to-moderate IgE-mediated asthma.
• To assess omalizumab's impact on nasal polyp score, obstruction, and asthma control.
• To explore effects on exacerbations, corticosteroid use, and type 2 inflammation biomarkers.

Main Methods:

• A randomized, controlled, open-label study involving 59 adult patients.
• Patients received either omalizumab plus standard therapy or standard therapy alone for 12 months.
• Primary endpoint: change in Nasal Polyp Score (NPS); secondary endpoints included asthma control and biomarkers.

Main Results:

• Omalizumab significantly reduced NPS compared to controls.
• Significant improvements were observed in nasal obstruction, asthma control, and type 2 inflammation biomarkers.
• Omalizumab use led to reduced asthma exacerbations and systemic corticosteroid exposure.

Conclusions:

• Omalizumab demonstrates efficacy in moderate CRSwNP patients with co-existing mild-to-moderate asthma.
• The findings suggest a potential role for omalizumab earlier in the treatment algorithm for selected patients.
• Larger, multicenter studies are needed to confirm these results.